Malaria Pv. MSP1
Description
Merozoite surface antigen is a protein located on the outside of the merozoite, playing an imperative role in immune reaction. About 45% cases of malaria are infected by Plasmodium vivax (Pv). Pv. MSP1 has to be used with Plasmodium falciparum (Pf) together for ELISA and rapid diagnostic test, Plasmodium falciparum and vivax infection takes about 95% of Plasmodium caused infection.
Recombinant Malaria Vivax MSP1 produced in E.coli and fused to a His tag was purified by proprietary chromatographic technique.
Product Specs
Product Science Overview
Malaria is a life-threatening disease caused by Plasmodium parasites, which are transmitted to humans through the bites of infected female Anopheles mosquitoes. Among the various species of Plasmodium, Plasmodium vivax is the most widespread human malaria parasite outside Africa, accounting for approximately 100 million cases each year . The development of an effective vaccine against P. vivax is crucial for malaria control and elimination efforts.
One of the leading vaccine candidates for P. vivax is the Merozoite Surface Protein-1 (MSP-1). MSP-1 is a large protein expressed on the surface of merozoites, the form of the parasite that invades red blood cells. It plays a critical role in the parasite’s ability to invade and multiply within red blood cells, making it an attractive target for vaccine development .
Recombinant MSP-1 refers to the laboratory-produced version of the MSP-1 protein. This recombinant protein is used in research and vaccine development to study the immune response and to develop potential vaccines. The 19 kDa fragment of MSP-1 (PvMSP-1 19) has been identified as a highly immunogenic region and is considered a promising vaccine candidate .
Studies have shown that the PvMSP-1 19 fragment is highly immunogenic, meaning it can induce a strong immune response in humans. This fragment has been found to be a target for naturally acquired antibodies in individuals living in malaria-endemic regions . The seroprevalence of antibodies against PvMSP-1 19 varies across different regions, with higher seroprevalence observed in areas where P. vivax is the dominant malaria species .
Research has demonstrated that natural infections with different Plasmodium species can induce antibodies reactive to a chimeric P. vivax recombinant protein, including PvMSP-1 . This indicates the potential of PvMSP-1 as a broadly immunogenic antigen for use in vaccine studies. Additionally, the PvMSP-1 19 fragment has shown improved ability to capture IgG antibodies from individuals infected with various Plasmodium species, further supporting its potential as a vaccine candidate .
